Lung Cancer-Targeted [131I]-Iodoshikonin as Theranostic Agent: Radiolabeling, In Vivo Pharmacokinetics and Biodistribution

Shikonin has been reported to exhibit high affinity toward lung cells and recited to inhibit the migration and invasion of lung cancer cells and suppress their growth. Shikonin cause noteworthy potential cytotoxic actions against A-549 lung cancer cells with IC 50 ≈ 3.5 μg/L per 10 4 cells. 131 I-sh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmaceutical chemistry journal 2022-02, Vol.55 (11), p.1163-1168
Hauptverfasser:	Selim, Adli A., Motaleb, M. A., Fayez, Hend A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Fenoterol Lung cancer Medicine Nuclear energy Organic Chemistry Pharmacology/Toxicology Pharmacy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	1168
container_issue	11
container_start_page	1163
container_title	Pharmaceutical chemistry journal
container_volume	55
creator	Selim, Adli A. Motaleb, M. A. Fayez, Hend A.
description	Shikonin has been reported to exhibit high affinity toward lung cells and recited to inhibit the migration and invasion of lung cancer cells and suppress their growth. Shikonin cause noteworthy potential cytotoxic actions against A-549 lung cancer cells with IC 50 ≈ 3.5 μg/L per 10 4 cells. 131 I-shikonin was created with a high radiochemical yield of 92 ± 2.5% under the optimized conditions. In vivo pharmacokinetic and biodistribution studies of the new labeled shikonin showed high lung uptake reaching 81.28 ± 2% injected dose per gram at 15 min post injection with a high lung/heart and lung/blood ratios. The newly synthesized [ 131 I]-iodoshikonin affords potential lung theranostic radiopharmaceutical. In conclusion, the results showed the potential use of [ 131 I]-iodoshikonin as a promising system for lung imaging.
doi_str_mv	10.1007/s11094-022-02553-x
format	Article
fullrecord	<record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A695453761</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A695453761</galeid><sourcerecordid>A695453761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-4da5798e3af0bd18b2ef47f08ecb50aed8fb43b0b03bc0df7ca4fb7d93a313873</originalsourceid><addsrcrecordid>eNp9kW9rFDEQh4MoeLZ-AV8FfNvUyWbT3fXdeWg9OLDItQgiYfJvL-1dIsleqf30TT3fFIoMw8DwewaGh5B3HE45QPehcA5Dy6Bpaksp2N0LMuOyE2wAwV-SGcDAGZfw4zV5U8o1QMVEMyP3q30c6QKjcZmtMY9ucpb-5IIvf7Flsqlswk2KIVIsdL1xGWMqUzB0Pro4faTf0Ya0Re22IY4ndBnpVbhN9GKDeYcm3YToarpQjJZ-CsmGMuWg91NI8Zi88rgt7u2_eUQuv3xeL76y1bfz5WK-YkbIfmKtRdkNvRPoQVve68b5tvPQO6MloLO9163QoEFoA9Z3BluvOzsIFFz0nTgi7w93R9w6FaJPU0azC8Wo-dkgWym6M15Tp8-kalm3CyZF50PdPwGaA2ByKiU7r37nsMP8R3FQj1LUQYqqUtRfKequQuIAlRqOo8vqOu1zrO__j3oAMvGRLA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Lung Cancer-Targeted [131I]-Iodoshikonin as Theranostic Agent: Radiolabeling, In Vivo Pharmacokinetics and Biodistribution</title><source>SpringerNature Journals</source><creator>Selim, Adli A. ; Motaleb, M. A. ; Fayez, Hend A.</creator><creatorcontrib>Selim, Adli A. ; Motaleb, M. A. ; Fayez, Hend A.</creatorcontrib><description>Shikonin has been reported to exhibit high affinity toward lung cells and recited to inhibit the migration and invasion of lung cancer cells and suppress their growth. Shikonin cause noteworthy potential cytotoxic actions against A-549 lung cancer cells with IC 50 ≈ 3.5 μg/L per 10 4 cells. 131 I-shikonin was created with a high radiochemical yield of 92 ± 2.5% under the optimized conditions. In vivo pharmacokinetic and biodistribution studies of the new labeled shikonin showed high lung uptake reaching 81.28 ± 2% injected dose per gram at 15 min post injection with a high lung/heart and lung/blood ratios. The newly synthesized [ 131 I]-iodoshikonin affords potential lung theranostic radiopharmaceutical. In conclusion, the results showed the potential use of [ 131 I]-iodoshikonin as a promising system for lung imaging.</description><identifier>ISSN: 0091-150X</identifier><identifier>EISSN: 1573-9031</identifier><identifier>DOI: 10.1007/s11094-022-02553-x</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Fenoterol ; Lung cancer ; Medicine ; Nuclear energy ; Organic Chemistry ; Pharmacology/Toxicology ; Pharmacy</subject><ispartof>Pharmaceutical chemistry journal, 2022-02, Vol.55 (11), p.1163-1168</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2022</rights><rights>COPYRIGHT 2022 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-4da5798e3af0bd18b2ef47f08ecb50aed8fb43b0b03bc0df7ca4fb7d93a313873</citedby><cites>FETCH-LOGICAL-c358t-4da5798e3af0bd18b2ef47f08ecb50aed8fb43b0b03bc0df7ca4fb7d93a313873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11094-022-02553-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11094-022-02553-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Selim, Adli A.</creatorcontrib><creatorcontrib>Motaleb, M. A.</creatorcontrib><creatorcontrib>Fayez, Hend A.</creatorcontrib><title>Lung Cancer-Targeted [131I]-Iodoshikonin as Theranostic Agent: Radiolabeling, In Vivo Pharmacokinetics and Biodistribution</title><title>Pharmaceutical chemistry journal</title><addtitle>Pharm Chem J</addtitle><description>Shikonin has been reported to exhibit high affinity toward lung cells and recited to inhibit the migration and invasion of lung cancer cells and suppress their growth. Shikonin cause noteworthy potential cytotoxic actions against A-549 lung cancer cells with IC 50 ≈ 3.5 μg/L per 10 4 cells. 131 I-shikonin was created with a high radiochemical yield of 92 ± 2.5% under the optimized conditions. In vivo pharmacokinetic and biodistribution studies of the new labeled shikonin showed high lung uptake reaching 81.28 ± 2% injected dose per gram at 15 min post injection with a high lung/heart and lung/blood ratios. The newly synthesized [ 131 I]-iodoshikonin affords potential lung theranostic radiopharmaceutical. In conclusion, the results showed the potential use of [ 131 I]-iodoshikonin as a promising system for lung imaging.</description><subject>Fenoterol</subject><subject>Lung cancer</subject><subject>Medicine</subject><subject>Nuclear energy</subject><subject>Organic Chemistry</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><issn>0091-150X</issn><issn>1573-9031</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kW9rFDEQh4MoeLZ-AV8FfNvUyWbT3fXdeWg9OLDItQgiYfJvL-1dIsleqf30TT3fFIoMw8DwewaGh5B3HE45QPehcA5Dy6Bpaksp2N0LMuOyE2wAwV-SGcDAGZfw4zV5U8o1QMVEMyP3q30c6QKjcZmtMY9ucpb-5IIvf7Flsqlswk2KIVIsdL1xGWMqUzB0Pro4faTf0Ya0Re22IY4ndBnpVbhN9GKDeYcm3YToarpQjJZ-CsmGMuWg91NI8Zi88rgt7u2_eUQuv3xeL76y1bfz5WK-YkbIfmKtRdkNvRPoQVve68b5tvPQO6MloLO9163QoEFoA9Z3BluvOzsIFFz0nTgi7w93R9w6FaJPU0azC8Wo-dkgWym6M15Tp8-kalm3CyZF50PdPwGaA2ByKiU7r37nsMP8R3FQj1LUQYqqUtRfKequQuIAlRqOo8vqOu1zrO__j3oAMvGRLA</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Selim, Adli A.</creator><creator>Motaleb, M. A.</creator><creator>Fayez, Hend A.</creator><general>Springer US</general><general>Springer</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20220201</creationdate><title>Lung Cancer-Targeted [131I]-Iodoshikonin as Theranostic Agent: Radiolabeling, In Vivo Pharmacokinetics and Biodistribution</title><author>Selim, Adli A. ; Motaleb, M. A. ; Fayez, Hend A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-4da5798e3af0bd18b2ef47f08ecb50aed8fb43b0b03bc0df7ca4fb7d93a313873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Fenoterol</topic><topic>Lung cancer</topic><topic>Medicine</topic><topic>Nuclear energy</topic><topic>Organic Chemistry</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Selim, Adli A.</creatorcontrib><creatorcontrib>Motaleb, M. A.</creatorcontrib><creatorcontrib>Fayez, Hend A.</creatorcontrib><collection>CrossRef</collection><jtitle>Pharmaceutical chemistry journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Selim, Adli A.</au><au>Motaleb, M. A.</au><au>Fayez, Hend A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lung Cancer-Targeted [131I]-Iodoshikonin as Theranostic Agent: Radiolabeling, In Vivo Pharmacokinetics and Biodistribution</atitle><jtitle>Pharmaceutical chemistry journal</jtitle><stitle>Pharm Chem J</stitle><date>2022-02-01</date><risdate>2022</risdate><volume>55</volume><issue>11</issue><spage>1163</spage><epage>1168</epage><pages>1163-1168</pages><issn>0091-150X</issn><eissn>1573-9031</eissn><abstract>Shikonin has been reported to exhibit high affinity toward lung cells and recited to inhibit the migration and invasion of lung cancer cells and suppress their growth. Shikonin cause noteworthy potential cytotoxic actions against A-549 lung cancer cells with IC 50 ≈ 3.5 μg/L per 10 4 cells. 131 I-shikonin was created with a high radiochemical yield of 92 ± 2.5% under the optimized conditions. In vivo pharmacokinetic and biodistribution studies of the new labeled shikonin showed high lung uptake reaching 81.28 ± 2% injected dose per gram at 15 min post injection with a high lung/heart and lung/blood ratios. The newly synthesized [ 131 I]-iodoshikonin affords potential lung theranostic radiopharmaceutical. In conclusion, the results showed the potential use of [ 131 I]-iodoshikonin as a promising system for lung imaging.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11094-022-02553-x</doi><tpages>6</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0091-150X
ispartof	Pharmaceutical chemistry journal, 2022-02, Vol.55 (11), p.1163-1168
issn	0091-150X 1573-9031
language	eng
recordid	cdi_gale_infotracmisc_A695453761
source	SpringerNature Journals
subjects	Fenoterol Lung cancer Medicine Nuclear energy Organic Chemistry Pharmacology/Toxicology Pharmacy
title	Lung Cancer-Targeted [131I]-Iodoshikonin as Theranostic Agent: Radiolabeling, In Vivo Pharmacokinetics and Biodistribution
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T05%3A41%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lung%20Cancer-Targeted%20%5B131I%5D-Iodoshikonin%20as%20Theranostic%20Agent:%20Radiolabeling,%20In%20Vivo%20Pharmacokinetics%20and%20Biodistribution&rft.jtitle=Pharmaceutical%20chemistry%20journal&rft.au=Selim,%20Adli%20A.&rft.date=2022-02-01&rft.volume=55&rft.issue=11&rft.spage=1163&rft.epage=1168&rft.pages=1163-1168&rft.issn=0091-150X&rft.eissn=1573-9031&rft_id=info:doi/10.1007/s11094-022-02553-x&rft_dat=%3Cgale_cross%3EA695453761%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A695453761&rfr_iscdi=true